Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

RayzeBio (RYZB) News Today

RayzeBio logo
Getting In on This "Macro-Trend"
RayzeBio, Inc. stock logo
Acuta Capital Partners LLC Makes New Investment in RayzeBio, Inc. (NASDAQ:RYZB)
Acuta Capital Partners LLC acquired a new position in shares of RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 344,571 shares of the company's stock
RayzeBio, Inc. stock logo
venBio Partners LLC Makes New $114.51 Million Investment in RayzeBio, Inc. (NASDAQ:RYZB)
venBio Partners LLC acquired a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 5,158,162 shares of the company's stock, valued at approximately $114,511,
Andreas Halvorsen's Firm Sells Out of RayzeBio Inc
RYZB Aug 2024 35.000 put
RYZB May 2024 55.000 put
BMY Mar 2024 54.000 put
RayzeBio, Inc. stock logo
Monashee Investment Management LLC Acquires Shares of 27,500 RayzeBio, Inc. (NASDAQ:RYZB)
Monashee Investment Management LLC bought a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 27,500 shares of the company's stock, valued at approximately $610,000. Ot
BMY Apr 2024 43.000 put
BMY Mar 2024 48.000 call
BMY Mar 2024 47.000 put
BMY Mar 2024 43.000 put
RYZB Feb 2024 65.000 call
RayzeBio, Inc. stock logo
Maven Securities LTD Makes New Investment in RayzeBio, Inc. (NASDAQ:RYZB)
Maven Securities LTD bought a new position in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 59,835 shares of the company's stock, valued at approximately $1,328,000. Maven
RayzeBio, Inc. stock logo
RayzeBio (NASDAQ:RYZB) Reaches New 12-Month High at $62.42
RayzeBio (NASDAQ:RYZB) Reaches New 12-Month High at $62.42
BMY Feb 2024 37.000 put
RayzeBio, Inc. stock logo
Vivo Capital LLC Acquires Shares of 633,576 RayzeBio, Inc. (NASDAQ:RYZB)
Vivo Capital LLC purchased a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 633,576 shares of the company's stock, valued at approximately $1
RayzeBio, Inc. stock logo
Versant Venture Management LLC Acquires New Stake in RayzeBio, Inc. (NASDAQ:RYZB)
Versant Venture Management LLC purchased a new position in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,158,161 shares of the company's stock, valued at a
RayzeBio, Inc. stock logo
Platinum Investment Management Ltd. Buys New Position in RayzeBio, Inc. (NASDAQ:RYZB)
Platinum Investment Management Ltd. bought a new stake in shares of RayzeBio, Inc. (NASDAQ:RYZB - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 222,222 shares of the company's stock, valued at a
IPO watch 2024: Which new stocks will hit the market?
IPO watch 2024: Which new stocks will hit the market? (RYZB)
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies.
white pills isolated on white background
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals (RYZB)
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
RayzeBio, Inc. stock logo
RayzeBio, Inc. (NASDAQ:RYZB) to Post FY2023 Earnings of ($3.25) Per Share, William Blair Forecasts
RayzeBio, Inc. (NASDAQ:RYZB - Free Report) - Investment analysts at William Blair increased their FY2023 EPS estimates for shares of RayzeBio in a research note issued on Tuesday, December 26th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($3.25) per share fo
RayzeBio just downgraded at JPMorgan, here's why
RayzeBio downgraded to Hold from Buy at Truist
Midday movers: Intel, RayzeBio, and more
RayzeBio: New IPO With Good Data And Solid Premise
Bristol Myers,RayzeBio deal, AstraZeneca buying Gracell
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RayzeBio, Inc. stock logo
RayzeBio's (RYZB) Market Perform Rating Reaffirmed at William Blair
William Blair reiterated a "market perform" rating on shares of RayzeBio in a research report on Tuesday.
Get RayzeBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYZB and its competitors with MarketBeat's FREE daily newsletter.

Top "Sleeping Giant" Crypto In The Market Now (Ad)

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late

RYZB Media Mentions By Week

RYZB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RYZB
News Sentiment

0.00

0.54

Average
Medical
News Sentiment

RYZB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RYZB Articles
This Week

0

1

RYZB Articles
Average Week

Get RayzeBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYZB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RYZB) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners